Bristol Myers beats quarterly revenue estimates on strong Opdivo sales
By Michael Erman (Reuters) -Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a hit from generic competition for several older drugs. Shares of the company were up 2% in premarket trading. Bristol Myers also raised its…